Key takeaways
Januvia is a popular DPP-4 inhibitor used to manage Type 2 diabetes, but it has no generic equivalent in the U.S. yet.
A generic version of Januvia may become available in 2026 after the expiration of its key patent.
Zituvio, a form of sitagliptin under a different brand name, is approved but not interchangeable with Januvia.
Januvia is a brand-name prescription drug approved by the FDA to manage Type 2 diabetes alongside diet and exercise. It works as a dipeptidyl peptidase-4 (DPP-4) inhibitor that slows the breakdown of hormones called incretins, which helps manage blood sugar levels. The patent for Januvia does not expire until November 2026, when other generic versions may start to become available.
Januvia generic availability |
|
|---|---|
| Generic name | Sitagliptin |
| Is there a generic available for sale in the U.S.? | No |
| When will a generic be available? | Estimated as early as the end of 2026 |
Is there a generic for Januvia?
No generic version of Januvia is available in the United States, but this could change in 2026 when the main patent expires. Two key patents protect Januvia and its combination with metformin (Janumet). The first patent, covering the dihydrogen phosphate salt of sitagliptin, expires on November 24, 2026. The second patent for Janumet lasts until January 21, 2029.
Merck, the company that makes these drugs, has been involved in legal disputes with Viatris over these patents. In addition, Merck has entered into deals with several generic manufacturers, allowing them to sell their versions of Januvia and Janumet as early as May 2026, and Janumet XR (extended-release tablets) by July 2026, subject to certain conditions. Generic approvals could provide more affordable options for people who need these medications.
While no generic version of Januvia is currently available, a generic version of sitagliptin is available under a different brand name: Zituvio, which received FDA approval in 2023. However, Zituvio is not a generic equivalent of Januvia.
What are the differences between generic vs. brand-name Januvia?
Generic and brand-name drugs must work in identical ways and meet the same safety and effectiveness standards. When a generic of Januvia becomes available, it may differ from the brand-name drug in appearance, inactive ingredients, and cost. Generic drugs are typically more accessible and less expensive than brand-name drugs.
Although many people may be interested in Zituvio as an alternative to Januvia, both drugs are not bioequivalent and can vary in different ways. Januvia contains sitagliptin phosphate, while Zituvio includes the free base form of sitagliptin. In addition, different manufacturers make them: Merck manufactures Januvia, while Zydus Pharmaceuticals makes Zituvio.
Keep in mind that Zituvio is not a generic version of Januvia. Healthcare providers may prescribe either form based on cost, availability, or other factors.
How much does generic Januvia cost?
A generic version of Januvia is not yet available on the market. Once it becomes available, it is expected to be significantly less expensive than the brand-name version. The average retail cost of Januvia is around $708 for 30, 100 mg tablets.
Prices for Januvia or other versions can vary by pharmacy and location. Although prices can change, using price comparison tools or checking with different pharmacies might help you find a better deal. Factors such as availability and regional demand can also influence the price.
Prescription discount cards, such as those from SingleCare, offer savings on the retail cost of Januvia. With a SingleCare card, Januvia could cost as low as around $286 for a 30-day supply of 100 mg tablets.
Save up to 80% on Januvia with SingleCare
Different pharmacies offer different prices for the same medication. SingleCare helps find the best price for you.
Is Januvia covered by insurance?
Januvia may be covered by commercial insurance plans, Medicare, or Medicaid. However, because it’s a brand-name drug, it may come with higher out-of-pocket costs. That’s because it’s usually placed on a higher tier of drug formularies or preferred drug lists. In other words, Januvia may not be a preferred drug for coverage.
If Januvia is covered, you may be responsible for a higher copay or coinsurance amount. The out-of-pocket cost could also depend on whether you’ve met your deductible. Some plans may have limitations on coverage, while others might not cover it at all.
Coverage can also differ between different insurance carriers and even between different plans from the same carrier. Therefore, it’s best to consult your insurance company to see whether Januvia is covered. If it’s not covered, you still have several options, including discount programs or manufacturer savings cards.
How do you get Januvia covered by insurance?
Insurers may have requirements they set to cover brand-name drugs like Januvia. You can always ask your insurance company ahead of time what they need to cover it.
In many cases, insurance plans require prior authorization, meaning a healthcare provider must submit documentation to demonstrate that the drug is medically necessary. They often have to include information about your overall medical history, blood sugar levels, and why Januvia could benefit your condition.
The process to get it covered may also involve trying other, lower-cost medications first (step therapy). That might mean trying metformin or other generic diabetes medications first and then documenting that they didn’t work well enough or caused intolerable side effects.
In any case, it’s important to work with a healthcare provider who can submit prior authorization paperwork on your behalf. The insurance company will then approve or deny the request. If the initial request is denied, you and your healthcare provider can submit an appeal to explain why Januvia is the best treatment option.
Generic alternatives to Januvia
Other diabetes medications are available that come in generic forms. Generic alternatives can be just as effective as Januvia and may be more accessible or covered by insurance.
Generic alternatives to Januvia include:
- Biguanides: This drug class helps reduce the production of sugar in the liver and improves insulin sensitivity. Glucophage (metformin) is the most common option and often the first drug prescribed for Type 2 diabetes. It’s also one of the most affordable diabetes medications.
- Sulfonylureas: These medications help the pancreas produce more insulin. Amaryl (glimepiride) and Glucotrol (glipizide) are both available as generics and often affordable alternatives.
- Thiazolidinediones (TZDs): This drug class improves insulin sensitivity in muscle and fat tissue. Actos (pioglitazone) is available as a generic and may be a lower-cost alternative to Januvia.
- DPP-4 inhibitors: These work similarly to Januvia by helping the body produce more insulin when blood sugar is high. Onglyza (saxagliptin) and Nesina (alogliptin) are both available as generics.
The most appropriate treatment option will depend on your overall health and other medications you take. A healthcare provider will assess the potential for side effects and drug interactions when recommending an alternative to Januvia.
Expert takeaway
Even though it contains the same active ingredient, Zituvio is not a true generic equivalent to Januvia. A healthcare provider may prescribe it instead of Januvia if it makes sense for the patient, but other generic alternatives to Januvia can work just as well.
The SingleCare prices in this article are the most accurate at the time of publishing in ZIP code 23666 as of Feb. 24, 2026.
- ClinCalc DrugStats Database, ClinCalc (2024)
- U.S. District Court rules in favor of Merck in sitagliptin phosphate patent lawsuit, Merck & Co., Inc. (2022)
- Januvia highlights of prescribing information, U.S. Food and Drug Administration (2023)
- Zituvio highlights of prescribing information, U.S. Food and Drug Administration (2023)
- Management of a prediabetes case with the DPP-4 inhibitor sitagliptin, Annals of Pharmacotherapy (2014)
- Sitagliptin decreases visceral fat and blood glucose in women with polycystic ovarian syndrome, The Journal of Clinical Endocrinology and Metabolism (2019)